期刊
CANCER CELL
卷 24, 期 1, 页码 120-129出版社
CELL PRESS
DOI: 10.1016/j.ccr.2013.06.002
关键词
-
资金
- National Health and Medical Research Council, Australia (NHMRC) [461221, 1016701]
- NHMRC IRIISS
- Victorian State Government through Victorian Cancer Agency
- Australian Cancer Research Foundation
- National Breast Cancer Foundation (NBCF)
- Qualtrough Family Bequest
- NHMRC Australia Fellowship
- NBCF Early Career Fellowship
- National Breast Cancer Foundation [NC-13-21, ECF-13-06] Funding Source: researchfish
The prosurvival protein BCL-2 is frequently overexpressed in estrogen receptor (ER)-positive breast cancer. We have generated ER-positive primary breast tumor xenografts that recapitulate the primary tumors and demonstrate that the BH3 mimetic ABT-737 markedly improves tumor response to the antiestrogen tamoxifen. Despite abundant BCL-XL expression, similar efficacy was observed with the BCL-2 selective inhibitor ABT-199, revealing that BCL-2 is a crucial target. Unexpectedly, BH3 mimetics were found to counteract the side effect of tamoxifen-induced endometrial hyperplasia. Moreover, BH3 mimetics synergized with phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors in eliciting apoptosis. Importantly, these two classes of inhibitor further enhanced tumor response in combination therapy with tamoxifen. Collectively, our findings provide a rationale for the clinical evaluation of BH3 mimetics in therapy for breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据